The fast diagnostic check gives a complete answer for detecting canine leishmaniosis that impacts one in 10 dogs in endemic areas
WESTBROOK, Maine, Nov. 8, 2023 /PRNewswire/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a world chief in pet healthcare innovation, introduced the upcoming launch of the SNAP® Leish 4Dx® Test, a complete screening check for vector-borne ailments, together with canine leishmaniosis. The SNAP Leish 4Dx Test makes use of the trusted SNAP 4Dx Plus testing platform, which detects Lyme illness, heartworm illness, ehrlichiosis, and anaplasmosis. By changing Lyme illness detection with detection of leishmaniosis, a extra prevalent endemic illness in sure areas of the world, the SNAP Leish 4Dx Test helps vector-borne illness analysis globally. The check shall be available in Europe and Asia starting February 2024.
Leishmaniosis is a probably deadly zoonotic illness transmitted to dogs by sand flies generally present in tropical and subtropical areas of Europe, Asia, Africa, and South and Central America. Early detection is essential; any canine residing in or touring to those endemic areas is inclined to an infection and ought to be examined, because the illness will be deadly if left untreated. Infected dogs can stay asymptomatic for months to years, making testing for leishmaniosis an integral part of annual wellness screens.
“In Leishmania-endemic areas globally, the place one in 10 dogs examined could also be optimistic, it is vital for practitioners to display screen wholesome dogs yearly for Leishmania antibodies, together with different widespread vector-borne pathogens, utilizing a qualitative, complete check with adequate sensitivity and specificity on the point-of-care,” stated Professor Guadalupe Miró, DEVPC, Veterinary Faculty, Universidad Complutense of Madrid, Spain. “For Leishmania-seropositive dogs, it is also extraordinarily necessary to quantify an infection stage and take into account outcomes from chemistry, CBC differentials, and urinalysis, so veterinarians can finest decide a therapy or monitoring plan.”
The launch of the SNAP Leish 4Dx Test gives veterinarians with an end-to-end answer for vector-borne illness testing, together with:
-
The capability to display screen for heartworm illness, ehrlichiosis, anaplasmosis, and leishmaniosis with a single pattern through the affected person go to.
-
Streamlined reference laboratory follow-up testing for quantification of SNAP positives and the chance to carry out further follow-up testing in-clinic or at IDEXX Reference Laboratories.
-
Compatibility with the SNAP Pro® Analyzer, which helps an environment friendly apply workflow by mechanically activating and deciphering check outcomes and facilitating seamless cost seize.
-
Ongoing assist and schooling to maintain veterinary workers up-to-date with the latest assets to assist defend pets and their households.
“Parasites and vector-borne ailments like leishmaniosis are an rising threat to the well being of pets globally,” stated Jay Mazelsky, IDEXX President and Chief Executive Officer. “This growth of our SNAP franchise demonstrates our dedication to increasing our vector-borne illness providing to assist veterinarians worldwide of their mission to ship the next customary of look after pets.”
For extra details about the SNAP platform, please go to idexx.com/en/veterinary/products/snap-tests/
About IDEXX
IDEXX is a world chief in pet healthcare innovation. Our diagnostic and software program services and products create readability within the complicated, continually evolving world of veterinary medication. We assist longer, fuller lives for pets by delivering insights and options that assist the veterinary group world wide make assured choices—to advance medical care, enhance effectivity, and build thriving practices. Our improvements additionally assist guarantee the protection of milk and water internationally and keep the well being and well-being of individuals and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs almost 11,000 folks and presents options and merchandise to prospects in additional than 175 nations and territories. For extra details about IDEXX, go to idexx.com.
Note Regarding Forward-Looking Statements
This information launch accommodates or could comprise forward-looking statements throughout the that means of the Private Securities Litigation Reform Act of 1995. Forward-looking statements will be recognized by means of phrases reminiscent of “expects,” “could,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “ought to,” “mission,” and comparable phrases and expressions. These forward-looking statements are supposed to offer our present expectations or forecasts of future occasions; are primarily based on present estimates, projections, beliefs, and assumptions; and aren’t ensures of future efficiency. Actual occasions or outcomes could differ materially from these described within the forward-looking statements. These statements are topic to dangers, uncertainties, assumptions, and different necessary components. Readers are cautioned to not put undue reliance on such forward-looking statements as a result of precise outcomes could range materially from these expressed or implied. The stories filed by IDEXX pursuant to United States securities legal guidelines comprise discussions of a few of these dangers and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether or not on account of new info, future occasions, or in any other case. Readers are suggested to evaluate IDEXX’s filings with the United States Securities and Exchange Commission (that are available from the SEC’s EDGAR database at sec.gov and through IDEXX’s web site at idexx.com).
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/idexx-expands-snap-platform-with-leish-4dx-test-to-support-veterinarians-globally-in-diagnosing-vector-borne-diseases-301978168.html
SOURCE IDEXX Laboratories, Inc.
